tbuckley/cabot-search huggingface dataset:
514. Potential of Bone Marrow Mesenchymal Stem Cells for Cystic Fibrosis Therapy
Authors: Guoshun Wang, Bruce A. Bunnell, Richard G. Painter, Susan Tom, Nicholas A. Lanson, Jeffery L. Spees, Donna Bertucci, Daniel J. Weiss, Vincent G. Valentine, Darwin J. Prockop, Jay K. Kolls
Journal: Molecular Therapy (2004)

Bone marrow mesenchymal stem cells (MSCs) have been shown to differentiate into pulmonary epithelial cells in animal models. To explore whether human MSCs can undergo differentiation into airway epithelia, which can be exploited as a novel gene therapy strategy for cystic fibrosis (CF), human MSCs expressing green florescent protein (GFP) were mixed with primary human airway epithelial cells in a ratio of 1:5, 1:10, or 1:20, and seeded on a semi-permeable filter membrane coated with human placenta collagen type VI. The cells were cultured at an air-liquid interface and were able to maintain the apical surface dry after one to two weeks with transepithelial resistance greater than 700 Ohms, suggesting the formation of tight junctions. Immunofluorescent staining with an antibody against cytokeratin 18 (CK18) demonstrated that the stem cells co-cultured with human airway cells expressed this epithelium-specific marker, whereas prior to the culture, there is no detectable CK18 expression by this approach. Morphologically, the GFP-labeled stem cells converted their original thin-spindle fibroblast shape or flat polygonal cell shape to a typical epithelial cuboidal shape with an accessory structure like cilia by confocal microscopy, suggesting that the hMSCs in the co-culture system transdifferentiate into airway epithelial cells. To confirm the finding, we further did immunostaining with an antibody against occludin, an epithelial tight junction protein. Flow cytometry and fluorescent microscopy showed that ~10% of the initially loaded GFP-MSCs express this critical epithelial marker. By cell sorting, we isolated the co-cultured hMSCs, and RT-PCR was performed with primers specific to human CFTR. The results demonstrated that the air-liquid culture induces hMSCs to express the CFTR gene. Furthermore, co-culture of normal hMSCs with CF airway epithelial cells resulted in the wild-type CFTR expression. More importantly, the MSCs isolated from CF patients were able to be gene-corrected. In vitro differentiation assays proved that the CFTR gene-corrected CF MSCs still possess their naive multipotency, such as differentiation along osteogenic, adipogenic, and chondrogenic pathways. The gene-corrected CF MSCs were able to contribute to apical Cl- secretion by chloride efflux assay in response to cAMP agonists. Conditions to increase the efficacy of MSC differentiation are currently under investigation. Therefore, we conclude that bone marrow mesenchymal stem cells may have potential applications in treating human airway diseases, such as CF.
Adhesion Prevention Strategies in Laparoscopic Surgery
Authors: George Pados, Anastasios Makedos, Basil Tarlatzis
Journal: Endoscopy (2013)

Adhesions are defined as abnormal attachments between tissues and organs [1]. Intra-ab‐ dominal adhesions may be classified as congenital or acquired [2]. Congenital adhesions are a consequence of embryological anomaly in the development of the peritoneal cavity. Ac‐ quired adhesions result from the inflammatory response of the peritoneum that arises after intra-abdominal inflammatory processes (e.g. acute appendicitis, pelvic inflammatory dis‐ ease, exposure to intestinal contents and previous use of intrauterine contraceptive devices), radiation and surgical trauma [3]. It has been reported that the majority of acquired adhe‐ sions (about 90%) are post-surgical [2].
Overall treatment success after treatment of primary superficial basal cell carcinoma: a systematic review and meta-analysis of randomized and nonrandomized trials
Authors: M.H. Roozeboom, A.H.H.M. Arits, P.J. Nelemans, N.W.J. Kelleners-Smeets
Journal: British Journal of Dermatology (2012)

Several noninvasive treatment modalities are available for superficial basal cell carcinoma (sBCC).This systematic review aims to determine residue, recurrence and tumour-free survival probabilities of patients with primary sBCC treated with the currently most frequently used therapies.The PubMed (January 1946 to October 2010), EMBASE (January 1989 to October 2010) and Cochrane (January 1993 to October 2010) databases, and reference lists were searched without date restriction. Inclusion criteria were studies that included primary, histologically proven sBCCs, that reported on residue and/or recurrence probabilities after treatment, and had a minimum follow-up period of 12 weeks. Both randomized and nonrandomized studies were included. The primary and secondary outcomes were the probability of complete response and tumour-free survival, respectively. Two independent reviewers selected 36 studies (14 randomized and 22 nonrandomized), and extracted residue, cumulative recurrence and tumour-free survival probabilities.Pooled estimates of percentages of sBCC with complete response at 12 weeks post-treatment, derived from 28 studies, were 86.2% [95% confidence interval (CI) 82-90%] for imiquimod treatment, and 79.0% (95% CI 71-87%) for photodynamic therapy (PDT). With respect to tumour-free survival at 1 year, the pooled estimates derived from 23 studies were 87.3% for imiquimod (95% CI 84-91%) and 84.0% for PDT (95% CI 78-90%). Only a small number of studies reported on the results of sBCC treatment with 5-fluorouracil (one), surgical excision (one) and cryotherapy (two).Pooled estimates from randomized and nonrandomized studies showed similar tumour-free survival at 1 year for imiquimod and PDT. The PDT tumour-free survival was higher in studies with repeated treatments. However, these results were largely derived from nonrandomized studies, and randomized studies with head-to-head comparison of imiquimod and PDT are lacking. There is a need for head-to-head comparison studies between PDT, imiquimod and other treatments with long-term follow-up to enable better recommendations for optimal sBCC treatment.
Abstract 813: Exercise Attenuates Heart failure in Cardiac Lipoprotein Lipase/CD36 Double Knockout Mice
Authors: Raffay S Khan, Kalyani G Bharadwaj, William S Blaner, Ira J Goldberg
Journal: Circulation (2009)

The adult heart derives 70% of its ATP from fatty acids (FA), many of which are delivered via lipoprotein lipase (LpL) mediated hydrolysis of lipoproteins, followed by diffusion or uptake through FAT/CD36. In heart failure, metabolism shifts towards increased glucose utilization and less FA oxidation. Mechanisms by which exercise improves heart function in heart failure are not fully understood. We hypothesized that exercise mediated improvements in heart function require improved substrate uptake via induction of LpL and CD36. We created 4 groups of mice ( n=9 –10/group ): control, CD36 Knockout ( Cd36  −/− ), cardiac LpL Knockout (hLpL0), and Double Knockout (DKO, hLpL0/ Cd36  −/− ). Heart lipid uptake, measured using radiolabeled human VLDL and mouse chylomicrons, showed a significant reduction in cardiac VLDL-TG uptake in hLpL0 (49±23%),  Cd36  −/−  (64±17%) and DKO (76±5%; p Cd36  −/−  mice, but was not statistically significant. Reduced uptake of chylomicron TG-derived FA however, was only found in DKO. Interestingly, loss of cardiac LpL reduced cardiac VLDL-cholesteryl ester (CE) uptake in hLpL0 (81%) and DKO (73%) (p CD36  −/−  mice. Similarly, vitamin A (RE) uptake was reduced in both hLpL0 and DKO mice but not in  CD36  −/− . Mice were assigned to sedentary or exercise (swimming) groups at 14 weeks. Cardiac function, assessed by echocardiography, was reduced in sedentary DKO mice (%fractional shortening (%FS) 26.6 vs 37.6 in controls; p Cd36  −/−  mice. Surprisingly, exercise training in DKO mice led to an improvement in %FS (33.6; p=0.09) and normalization of heart failure gene expression (p
Organized proteomic heterogeneity in colorectal cancer liver metastases and implications for therapies
Authors: Andrei Turtoi, Arnaud Blomme, Delphine Debois, Joan Somja, David Delvaux, Georgios Patsos, Emmanuel Di Valentin, Olivier Peulen, Eugène Nzaramba Mutijima, Edwin De Pauw, Philippe Delvenne, Olivier Detry, Vincent Castronovo
Journal: Hepatology (2013)

Tumor heterogeneity is a major obstacle for developing effective anticancer treatments. Recent studies have pointed to large stochastic genetic heterogeneity within cancer lesions, where no pattern seems to exist that would enable a more structured targeted therapy approach. Because to date no similar information is available at the protein (phenotype) level, we employed matrix assisted laser desorption ionization (MALDI) image-guided proteomics and explored the heterogeneity of extracellular and membrane subproteome in a unique collection of eight fresh human colorectal carcinoma (CRC) liver metastases. Monitoring the spatial distribution of over 1,000 proteins, we found unexpectedly that all liver metastasis lesions displayed a reproducible, zonally delineated pattern of functional and therapeutic biomarker heterogeneity. The peritumoral region featured elevated lipid metabolism and protein synthesis, the rim of the metastasis displayed increased cellular growth, movement, and drug metabolism, whereas the center of the lesion was characterized by elevated carbohydrate metabolism and DNA-repair activity. From the aspect of therapeutic targeting, zonal expression of known and novel biomarkers was evident, reinforcing the need to select several targets in order to achieve optimal coverage of the lesion. Finally, we highlight two novel antigens, LTBP2 and TGFBI, whose expression is a consistent feature of CRC liver metastasis. We demonstrate their in vivo antibody-based targeting and highlight their potential usefulness for clinical applications.The proteome heterogeneity of human CRC liver metastases has a distinct, organized pattern. This particular hallmark can now be used as part of the strategy for developing rational therapies based on multiple sets of targetable antigens.
Risk Stratification for In-Hospital Mortality in Acutely Decompensated Heart Failure—Reply
Authors: Gregg C. Fonarow, Kirkwood F. Adams, William T. Abraham, Clyde W. Yancy, W. John Boscardin
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Keratotsis punctata of the palmar creases: report of two cases associated with ichthyosis vulgaris
Authors: None Just, None Ribera, None Bielsa, None Calatrava, None Ferrándiz
Journal: British Journal of Dermatology (1999)

Two patients with keratosis punctata of the palmar creases are described. The association with ichthyosis vulgaris and other disorders of keratinization is discussed. In both cases, histopathology revealed a close relation between the keratotic plug and the sweat glands. The role of genetic factors and manual activity in the pathogenesis is discussed. Treatment with oral etretinate resulted in a good improvement in the first patient, but prolonged low‐dose maintenance therapy was required to prevent recurrence.
ATELECTASIS IN UPPER RESPIRATORY INFECTIONS IN POST-TRAUMATIC PARALYZED PATIENTS
Authors: R L FRIEDMAN
Journal: Annals of Internal Medicine (1954)

Article1 May 1954ATELECTASIS IN UPPER RESPIRATORY INFECTIONS IN POST-TRAUMATIC PARALYZED PATIENTSROBERT L. FRIEDMAN, M.D.ROBERT L. FRIEDMAN, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-40-5-924 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptPulmonary atelectasis in post-traumatic paralyzed patients, more frequently quadriplegics than paraplegics, occurs not uncommonly during an upper respiratory infection. However, a discussion of this topic was not found in a review of the available medical literature.Atelectasis which occurs in postoperative cases and in poliomyelitis has been rather frequently described. Morrow and Stimson2 described four cases of atelectasis in poliomyelitis and many similar instances have been observed. Jacobson et al.,1 in a recent paper on pulmonary complications in acute bulbar poliomyelitis, observe that atelectasis is the most frequent and most fatal complication.This hospital has a cord injury service of...Bibliography1. JacobsonCohenCarter GSRRA: Pulmonary complications of acute bulbar poliomyelitis, Radiology 57: 629-641, 1951. CrossrefMedlineGoogle Scholar2. MorrowStimson DJPM: Atelectasis in poliomyelitis, M. Clin. North America 31: 609-625, 1947. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Columbus, Ohio*Received for publication November 6, 1953.From the Department of Radiology, McGuire Veterans Hospital, Richmond, Virginia.Reviewed in the Veterans Administration and published with the approval of the Chief Medical Director. The statements and conclusions published by the author are the result of his own study and do not necessarily reflect the opinion or policy of the Veterans Administration. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byLOCALIZED PULMONARY DISEASESDie Lungenatelektase 1 May 1954Volume 40, Issue 5Page: 924-931KeywordsDiagnostic radiologyPoliomyelitisPulmonary diseasesUpper respiratory tract infectionsVentilators ePublished: 1 December 2008 Issue Published: 1 May 1954 PDF downloadLoading ...
Countdown to 2015 for maternal, newborn, and child survival: the 2008 report on tracking coverage of interventions
Authors: Jennifer Bryce, Bernadette Daelmans, Archana Dwivedi, Vincent Fauveau, Joy E Lawn, Elizabeth Mason, Holly Newby, Anuraj Shankar, Ann Starrs, Tessa Wardlaw
Journal: The Lancet (2008)
EVALUATION OF THERAPY IN CHRONIC ATROPHIC ARTHRITIS
Authors: W. Paul Holbrook
Journal: Annals of Internal Medicine (1933)

Article1 October 1933EVALUATION OF THERAPY IN CHRONIC ATROPHIC ARTHRITISW. PAUL HOLBROOK, M.D., F.A.C.P.W. PAUL HOLBROOK, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-7-4-457 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe treatment of chronic arthritis is still passing through a phase of promiscuous therapy, much as tuberculosis did 20 years ago. There has been a tremendous increase in interest concerning rheumatic diseases during the past ten years, and, as a result, the medical literature has been flooded with reports of cures accomplished by all conceivable types of treatment. As a consequence, the majority of clinicians have been unable to separate fact from fancy. Diets, vaccines, colonic irrigations, various forms of electro-, physio-, and hydrotherapy, typhoid vaccine injections, the administration of scores of chemicals orally or by injections, endocrine therapy, postural... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Tucson, Arizona*Read at the Montreal Meeting of the American College of Physicians, February 10, 1933.From the Desert Sanatorium and Institute of Research, Tucson, Arizona. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 October 1933Volume 7, Issue 4Page: 457-467KeywordsArthritisDietEndocrine therapyTyphoidVaccines ePublished: 1 December 2008 Issue Published: 1 October 1933 PDF downloadLoading ...
Scientists Explore Pathogenesis of IBD
Authors: Tracy Hampton
Journal: JAMA (2004)

CHICAGO—While inflammatory bowel disease (IBD) has been studied and treated for decades, it remains mysterious in many ways. Various complex factors keep researchers guessing why some individuals develop Crohn disease or ulcerative colitis (the conditions that fall under the label of IBD), while others are never afflicted. But science is making headway, and researchers are beginning to paint a picture of IBD that includes genetic susceptibility, an abnormal balance between beneficial and pathogenic bacteria in the gastrointestinal tract, defects in the integrity of the intestinal epithelium, and a disregulated immune response of the host. It is now believed that a combination of these factors is necessary for IBD to develop. At the Third Annual Advances in Inflammatory Bowel Diseases conference held here in October, experts in the field discussed the pathogenesis of IBD and potential treatment strategies that might be used to manage the disease.
Lori Mosca, MD, PhD
Authors: Lori Mosca
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
DOGGER BANK ITCH..
Authors: R. H. Seville
Journal: British Journal of Dermatology (1957)

Journal Article DOGGER BANK ITCH.: Reaport of a Case Get access R. H. Seville, M.D., M.R.C.P. R. H. Seville, M.D., M.R.C.P. Dermatologist, Royal Infirmary and Beaumont Hospital, Lancaster Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 69, Issue 3, 1 March 1957, Pages 92–93, https://doi.org/10.1111/j.1365-2133.1957.tb13235.x Published: 01 March 1957
Abstract 891: Urinary ADAM12 levels detect the presence of pancreatic cancer
Authors: Roopali Roy, David Zurakowski, Matthew Kulke, Marsha A. Moses
Journal: Cancer Research (2014)

Abstract Pancreatic malignancies are the fourth leading cause of all cancer-related deaths of both men and women in the United States. Each year, approximately 32,000 new patients are diagnosed with this disease and nearly the same number die from it. A majority of patients with pancreatic malignancies, including both pancreatic ductal adenocarcinoma (PDAC) and pancreatic neuroendocrine tumors (pNET) present with advanced disease due to a lack of specific symptoms and current diagnostic limitations, making this disease extremely difficult to detect. The combination of poor prognosis and late presentation of pancreatic cancer patients highlights the urgent need for the development of effective, early detection strategies for this disease. Our laboratory has established a comprehensive biomarker discovery initiative whose objective is to identify proteins present in urine of cancer patients, to determine whether their presence might be relevant to disease status and stage and to validate their diagnostic and prognostic efficacy in large scale clinical trials. In the current study, our goal was to determine whether ADAM12 (a disintegrin and metalloprotease 12) could be detected in the urine of patients with pancreatic malignancies and whether ADAM12 levels might serve as an independent predictor of disease status. Retrospective analyses of urine samples (n=130) from PDAC and pNET patients as well as age- and sex-matched controls were conducted. Urinary ADAM12 levels were determined using a monospecific ELISA system. In addition, ADAM12 protein expression in tumor and normal pancreatic tissues was analyzed via immunohistochemistry (IHC). Multivariable logistic regression analyses indicated that, when controlling for age and sex, urinary ADAM12 could serve as significant independent predictor for distinguishing PDAC (P&amp;lt;0.001) and pNET (P&amp;lt;0.008) patients from healthy controls. Kaplan-Meier analysis of estimated patient survival stratified by urinary ADAM12 levels indicated a significantly shorter patient survival time for PDAC patients with high ADAM12 levels (P=0.015) compared to patients with lower urinary ADAM12. In addition, IHC analysis indicated that ADAM12 protein expression was upregulated ∼4-fold in Grade I-III PDAC compared to normal pancreatic tissue. Taken together, our results suggest that the measurement of ADAM12 levels may have diagnostic value in detection and/or clinical monitoring of disease status in patients with pancreatic malignancies. [Supported by: The Advanced Medical Foundation] Citation Format: Roopali Roy, David Zurakowski, Matthew Kulke, Marsha A. Moses. Urinary ADAM12 levels detect the presence of pancreatic cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 891. doi:10.1158/1538-7445.AM2014-891